Success Metrics

Clinical Success Rate

80.0%

Based on 4 completed trials

Completion Rate

80%(4/5)

Active Trials

0(0%)

Results Posted

0%(0 trials)

Terminated

1(20%)

Phase Distribution

Ph phase_2

80%

Ph phase_3

20%

Phase Distribution

Early Stage

Mid Stage

Late Stage

Phase Distribution5 total trials

Phase 2Efficacy & side effects

4(80.0%)

Phase 3Large-scale testing

1(20.0%)

Highest Phase Reached

Phase 3

Trial Status & Enrollment

Completion Rate

80.0%

4 of 5 finished

Non-Completion Rate

20.0%

1 ended early

Currently Active

trials recruiting

Total Trials

all time

Status Distribution

Completed(4)

Terminated(1)

Detailed Status

Completed4

Terminated1

Development Timeline

Analytics

Development Status

Total Trials

Active

Success Rate

80.0%

Most Advanced

Phase 3

Trials by Phase

Phase 24 (80.0%)

Phase 31 (20.0%)

Trials by Status

completed480%

terminated120%

Recent Activity

0 active trials

Showing 5 of 5

completedphase_2

Masitinib in Relapse or Refractory Multiple Myeloma With t(4/14) Translocation Expressing or Not FGFR3

NCT00866138

terminatedphase_3

Masitinib in Combination With FOLFIRI for Second-line Treatment of Patients With Metastatic Colorectal Cancer

NCT02605044

completedphase_2

Clinical Trials (5)

Showing 5 of 5 trials

NCT00866138Phase 2

Masitinib in Relapse or Refractory Multiple Myeloma With t(4/14) Translocation Expressing or Not FGFR3

Completed

NCT02605044Phase 3

Masitinib in Combination With FOLFIRI for Second-line Treatment of Patients With Metastatic Colorectal Cancer

Terminated

NCT00976118Phase 2

Activity of Masitinib (AB1010) in Mild to Moderate Alzheimer's Disease

Completed

NCT00831974Phase 2

Efficacy of AB1010 in Patients With Systemic Indolent Mastocytosis

Completed

NCT00831922Phase 2

Efficacy of Oral AB1010 in Adult Patients With Active Rheumatoid Arthritis

Completed

All 5 trials loaded

Drug Details

Intervention Type: DRUG
Total Trials: 5